Abstract:Background: Tuberculosis (TB) is a major global health problem in the whole world, especially in the developing countries. We aimed to assess diagnostic accuracy and safety of a novel ESAT6-CFP10 (EC) skin test for TB infection in Chinese adults.Methods: We conducted randomized, double-blinded, parallel-group clinical trials at two sites in healthy adults and TB/non-TB patients, respectively. TB infection-free healthy participants in a ratio of 1:1:1:1 to receive BCG vaccine or placebo, followed by EC skin test (0·5μg/0·1ml), or EC (1μg/0·1ml), along with the TST, T-SPOT.TB test, 12 weeks after the vaccination. TB patients or non-TB patients with pulmonary disease were randomly allocated in a ratio of 1:1 to receive EC skin test at 0·5μg/0·1ml, or 1μg/0·1ml, along with the TST and T-SPOT.TB test. The diameter of the skin indurations and/or redness at the injection sites were measured at 24 hours, 48 hours, and 72 hours after the skin tests. The studies was registered with ClinicalTrials.gov, number NCT02389322 and NCT02336542.Findings: We enrolled 223 TB infection-free healthy participants after screening, and randomly allocated them to receive BCG vaccination or placebo vaccination. Of them, 83 and 86 complete the EC skin test at 0·5μg/0·1ml or 1μg/0·1ml after vaccination. 96 TB patients and 95 non-TB patients with pulmonary diseases were allocated to receive the EC skin test at 0·5μg/0·1ml or 1μg/0·1ml, respectively. EC skin test at 1μg/0·1ml was found to be superior to 0·5μg/0·1ml based on the estimated AUCs, and the maximum AUCs of 0·927 was obtained at 1μg/0·1ml EC skin test at 48 hours using diameters of redness or induration as indicator. The highest diagnostic values achieved with cutoff values between 3·7~6·3 mm, and 5mm was determined as positive cutoff value for the responses of EC skin test. The incidence of adverse reaction following the EC skin tests were 27·8%, and no serious adverse event related to the EC skin tests was observed.Interpretation: The experimental EC skin test has an acceptable safety proﬁle. EC skin test at 1μg/0·1ml can achieve both high specificity and sensitivity, and was selected as optimal dose for future studies.Funding: National Science and Technology Major Project (2012ZX10004710) Zhifei Longcom Biologic Pharmacy Co., China.Declaration of Interest: We declare no competing interests.Ethical Approval: We obtained approvals from the institutional review boards of the Jiangsu Provincial Center of Disease Control and Prevention, and Shanghai Public Health Clinical Center before initiation of the studies. Written informed consent were obtained from all participants. The trials were conducted in accordance with the Declaration of Helsinki and Good Clinical Practice.

High Accuracy of Recombinant Fusion Protein ESAT6-CFP10 Skin Test for the Detection of Tuberculosis Infection: A Phase III, Multi-centered, Double-blind, Hospital-based, Randomized Controlled Trial

High Accuracy of Recombinant Fusion Protein Early Secretory Antigenic Target Protein 6‐culture Filtrate Protein 10 Skin Test for the Detection of Tuberculosis Infection: a Phase III, Multi‐centered, Double‐blind, Hospital‐based, Randomized Controlled Trial

Sensitivity, Specificity, and Safety of a Novel ESAT6-CFP10 Skin Test for Tuberculosis Infection in China: 2 Randomized, Self-Controlled, Parallel-Group Phase 2b Trials

Recombinant fusion ESAT6-CFP10 immunogen as a skin test reagent for tuberculosis diagnosis: an open-label, randomized, two-centre phase 2a clinical trial

Utility of Recombinant Fusion Protein ESAT6-CFP10 Skin Test for Differential Diagnosis of Active Tuberculosis: A Prospective Study.

Safety of Recombinant Fusion Protein ESAT6-CFP10 as a Skin Test Reagent for Tuberculosis Diagnosis: an Open-Label, Randomized, Single-Center Phase I Clinical Trial

Sensitivity, Specificity and Safety of a Novel Skin Test (ESAT6-CFP10) for Tuberculosis Infection in China: Randomized, Blinded, Self-Controlled, Parallel-Group Phase 2b Trials

Clinical Application and Antigenicity of ESAT-6/CFP-10 Fusion Protein in Diagnosis of Tuberculosis

Induration or erythema diameter not less than 5 mm as results of recombinant fusion protein ESAT6-CFP10 skin test for detecting M. tuberculosis infection

Preparation of Immunochromatographic Strips for Rapid Detection of Early Secreted Protein ESAT-6 and Culture Filtrate Protein CFP-10 from Mycobacterium Tuberculosis.

Novel Monoclonal Antibodies To Esat-6 And Cfp-10 Antigens For Elisa-Based Diagnosis Of Pleural Tuberculosis

Diagnostic performance of a novel ESAT6-CFP10 skin test for tuberculosis infection in school tuberculosis outbreak in China

Safety of a Novel ESAT6-CFP10 skin test compared with tuberculin skin test in a double-blind, randomized, controlled study

Evaluation of enzyme-linked immunospot assay detecting Mycobacterium tuberculosis specific T cell responses in patients with pulmonary tuberculosis

Clinical Application of T-SPOT.TB in Diagnosis of HIV/AIDS and TB Patients

Diagnostic Performance of a Novel Mycobacterium Tuberculosis Specific T-Cell Based Assay for Tuberculosis

Age and CD4 + T cell count influence ESAT6-CFP10 skin test results in patients with tuberculosis

Evaluation of a New IFN-γ Release Assay for Rapid Diagnosis of Active Tuberculosis in a High-Incidence Setting.

Picogram level electrochemical impedimetric immunosensor for monitoring Mycobacterium tuberculosis based on specific and sensitive ESAT-6 monoclonal antibody

A New Method of Tuberculosis Infection Diagnosis—Enzyme-Linked Immunospot Assay

Evaluation of Gamma Interferon Release Assays Using Mycobacterium Tuberculosis Antigens for Diagnosis of Latent and Active Tuberculosis in Mycobacterium Bovis Bcg-Vaccinated Populations